Compare MTRX & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTRX | PRLD |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | United States | United States |
| Employees | 2239 | N/A |
| Industry | Engineering & Construction | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.0M | 391.1M |
| IPO Year | 1995 | 2020 |
| Metric | MTRX | PRLD |
|---|---|---|
| Price | $12.41 | $3.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $17.00 | $5.67 |
| AVG Volume (30 Days) | 204.5K | ★ 484.2K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | N/A | N/A |
| Revenue | ★ $769,286,000.00 | $12,140,000.00 |
| Revenue This Year | $19.75 | $320.10 |
| Revenue Next Year | $7.96 | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.64 | ★ 73.43 |
| 52 Week Low | $9.88 | $0.75 |
| 52 Week High | $16.11 | $5.69 |
| Indicator | MTRX | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 44.62 | 35.95 |
| Support Level | $11.79 | $3.40 |
| Resistance Level | $12.62 | $4.13 |
| Average True Range (ATR) | 0.44 | 0.32 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 42.16 | 3.85 |
Matrix Service Co provides engineering, fabrication, construction, maintenance, and repair services prominently to the energy and industrial markets. The company operates through three main segments: Storage and Terminal Solutions, Utility and Power Infrastructure, and Process and Industrial Facilities. These segments cover services like building and maintaining storage tanks and terminals, supporting power delivery and new power generation projects including renewables, as well as plant maintenance and turnarounds for refining and petrochemical industries. Matrix generates revenue by delivering these services to clients in oil, gas, power, and petrochemical sectors across North America and internationally.
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.